VERU — Veru Inc.

VERU Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $5.3 million or $0.26 per diluted share, improved from a net loss of $8.9 million or $0.61 per diluted share in the prior year.
• Research and Development Costs: Decreased to $1.3 million from $5.7 million year-over-year, attributed to the completion of the Phase 2b clinical study for Novosarm.
• General and Administrative Expenses: Reduced to $4.1 million from $5.2 million, primarily due to lower share-based compensation.
• Cash Position: As of December 31, 2025, cash, cash equivalents, and restricted cash totaled $33 million, up from $15.8 million at the end of the previous quarter.
• Net Working Capital: Increased to $29.7 million from $11.1 million as of September 30, 2025.
• Cash Used in Operations: $6.2 million for the quarter, down from $11.3 million in the prior year.

2. Strategic Updates and Business Highlights

• Drug Development: Focus on two key assets, Novosarm (for obesity treatment) and sabizabulin (anti-inflammatory agent).
• Novosarm Clinical Trials: Completed a positive Phase 2b trial demonstrating improved fat loss while preserving lean mass in older patients. Plans for a Phase 2b PLATO study are underway, targeting patients initiating semaglutide treatment.
• Regulatory Pathways: FDA provided clarity on potential approval pathways for Novosarm, emphasizing the importance of preserving lean mass and physical function.
• Bone Mineral Density: Novosarm may also serve as a treatment to improve bone mineral density in postmenopausal women, a significant advantage over current GLP-1 treatments.

3. Forward Guidance and Outlook

• Cash Sufficiency: Current cash reserves are expected to fund operations through the interim analysis of the Phase 2b PLATO study.
• Clinical Study Timeline: The Phase 2b PLATO study is set to begin in Q1 2026, with an interim analysis anticipated in 2027.

4. Bad News, Challenges, or Points of Concern

• Continued Losses: The company remains unprofitable with ongoing negative cash flow from operations.
• Regulatory Risks: While there are potential pathways for Novosarm approval, the need to demonstrate both weight loss and functional benefits adds complexity to the development process.
• Market Competition: The obesity treatment market is competitive, particularly with established GLP-1 receptor agonists, which may pose challenges for Novosarm's market entry.

5. Notable Q&A Insights

• Choice of Semaglutide: Management opted for injectable semaglutide in the PLATO study to minimize variability and ensure consistency in results compared to previous studies.
• FDA Discussion on Functional Benefits: The FDA has acknowledged the use of stair climb tests as a valid measure for assessing functional benefits, with specific guidelines for conducting these assessments.
• Interim Analysis: There are no pre-specified futility analyses or sample size adjustments planned for the interim analysis, focusing instead on confirming positive trends in lean mass preservation and fat loss.

This summary encapsulates the key financial and strategic aspects of Veru's Q1 2026 earnings call, highlighting both the progress made and the challenges ahead.